
Immuno-Oncology
The crowd matters.
For far too long, we the people who want to give and get better care have had no say in what new ideas get into practice. When you support new ideas here they are over 20 times more likely to get out to market - sometimes incredibly fast. So explore, like, try, pilot, partner, mentor, or invest in these companies and ideas and let's fix healthcare, one awesome idea at a time!
See the companies ↓Part of Cancer & Oncology
Fyggy's top 8 in Immuno-Oncology
Ranked by MedStartr Engagement Score.
- 1MedGenomeMedStartr Engagement Score5MedStartr Engagement Score5
- 1Apricity HealthMedStartr Engagement Score5MedStartr Engagement Score5
- 1PersonalisMedStartr Engagement Score5MedStartr Engagement Score5
- 1Nilogen OncosystemsMedStartr Engagement Score5MedStartr Engagement Score5
- 1Turnstone BiologicsMedStartr Engagement Score5MedStartr Engagement Score5
- 1BioGraph 55MedStartr Engagement Score5MedStartr Engagement Score5
- 1NoetikMedStartr Engagement Score5MedStartr Engagement Score5
- 8neoX (星亢原)MedStartr Engagement Score4MedStartr Engagement Score4
Companies in Immuno-Oncology
Only accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join now
Andreessen Horowitz
San Francisco, CA, United States
Andreessen Horowitz is a venture capital firm based in San Francisco, California. The firm is associated with prominent individuals like Chris Dixon and Davide Ulevitch and coll...
...moreOnly accessible to MedStartr community members.
Join nowOnly accessible to MedStartr community members.
Join nowImmuno-Oncology Salon
Share photos and talk with people who care about Immuno-Oncology. Please follow the community rules.
Sign in to join the conversation.
Sign in to comment